X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with Orchid Chemicals - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs ORCHID PHARMA LTD - Comparison Results

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA ORCHID PHARMA LTD SHASUN PHARMA/
ORCHID PHARMA LTD
 
P/E (TTM) x 123.9 -0.5 - View Chart
P/BV x 8.5 0.4 2,305.1% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 SHASUN PHARMA   ORCHID PHARMA LTD
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
ORCHID PHARMA LTD
Sep-13
SHASUN PHARMA/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs94194 48.6%   
Low Rs4635 130.3%   
Sales per share (Unadj.) Rs214.2276.5 77.5%  
Earnings per share (Unadj.) Rs5.3-79.2 -6.7%  
Cash flow per share (Unadj.) Rs15.8-43.5 -36.4%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %1.40-  
Book value per share (Unadj.) Rs53.353.9 98.9%  
Shares outstanding (eoy) m56.6270.45 80.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.30.4 78.8%   
Avg P/E ratio x13.1-1.4 -906.2%  
P/CF ratio (eoy) x4.4-2.6 -167.7%  
Price / Book Value ratio x1.32.1 61.7%  
Dividend payout %18.70-   
Avg Mkt Cap Rs m3,9588,067 49.1%   
No. of employees `000NA2.8 0.0%   
Total wages/salary Rs m2,1642,527 85.6%   
Avg. sales/employee Rs ThNM6,956.1-  
Avg. wages/employee Rs ThNM902.5-  
Avg. net profit/employee Rs ThNM-1,993.0-  
INCOME DATA
Net Sales Rs m12,12719,477 62.3%  
Other income Rs m229407 56.3%   
Total revenues Rs m12,35619,884 62.1%   
Gross profit Rs m1,0091,103 91.5%  
Depreciation Rs m5942,519 23.6%   
Interest Rs m4155,227 7.9%   
Profit before tax Rs m230-6,236 -3.7%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m-73-125 58.1%   
Profit after tax Rs m302-5,580 -5.4%  
Gross profit margin %8.35.7 147.0%  
Effective tax rate %-31.72.0 -1,576.9%   
Net profit margin %2.5-28.7 -8.7%  
BALANCE SHEET DATA
Current assets Rs m6,88411,014 62.5%   
Current liabilities Rs m8,45632,060 26.4%   
Net working cap to sales %-13.0-108.1 12.0%  
Current ratio x0.80.3 237.0%  
Inventory Days Days6295 65.0%  
Debtors Days Days10834 320.5%  
Net fixed assets Rs m4,97029,440 16.9%   
Share capital Rs m113705 16.1%   
"Free" reserves Rs m2,8752,043 140.7%   
Net worth Rs m3,0203,800 79.5%   
Long term debt Rs m1,8179,018 20.2%   
Total assets Rs m13,34746,510 28.7%  
Interest coverage x1.6-0.2 -804.3%   
Debt to equity ratio x0.62.4 25.4%  
Sales to assets ratio x0.90.4 217.0%   
Return on assets %5.4-0.8 -707.0%  
Return on equity %10.0-146.9 -6.8%  
Return on capital %13.3-3.7 -356.7%  
Exports to sales %46.437.9 122.4%   
Imports to sales %14.222.6 63.0%   
Exports (fob) Rs m5,6227,378 76.2%   
Imports (cif) Rs m1,7284,406 39.2%   
Fx inflow Rs m5,8437,513 77.8%   
Fx outflow Rs m2,1735,649 38.5%   
Net fx Rs m3,6691,865 196.8%   
CASH FLOW
From Operations Rs m3981,682 23.6%  
From Investments Rs m-1,635-9,860 16.6%  
From Financial Activity Rs m1,3096,644 19.7%  
Net Cashflow Rs m71-1,535 -4.6%  

Share Holding

Indian Promoters % 39.2 32.3 121.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 4.6 78.3%  
FIIs % 17.6 3.3 533.3%  
ADR/GDR % 0.0 4.6 -  
Free float % 39.6 55.3 71.6%  
Shareholders   20,750 84,811 24.5%  
Pledged promoter(s) holding % 12.3 54.9 22.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   SANOFI INDIA  ABBOTT INDIA  PLETHICO PHARMA  CIPLA  NOVARTIS  

Compare SHASUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 8-QTR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS